Chembio Diagnostics Inc. Daily Stock Analysis

Daily Stock Analysis, CEMI, Chembio Diagnostics Inc, priceseries

Chembio Diagnostics Inc. Daily Stock Analysis
Stock Information
Open
0.81
Close
0.77
High
0.84
Low
0.75
Previous Close
0.79
Daily Price Gain
-0.02
YTD High
1.25
YTD High Date
Jan 3, 2022
YTD Low
0.75
YTD Low Date
Mar 7, 2022
YTD Price Change
-0.46
YTD Gain
-37.40%
52 Week High
7.34
52 Week High Date
Jul 22, 2021
52 Week Low
0.75
52 Week Low Date
Mar 7, 2022
52 Week Price Change
-3.99
52 Week Gain
-83.82%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Apr 7. 2017
5.45
May 17. 2017
6.62
27 Trading Days
21.48%
Link
LONG
Dec 15. 2017
7.30
Jan 22. 2018
8.66
23 Trading Days
18.59%
Link
LONG
May 10. 2018
8.15
May 24. 2018
8.58
10 Trading Days
5.29%
Link
LONG
Jan 4. 2019
6.00
Feb 6. 2019
6.79
22 Trading Days
13.23%
Link
LONG
Apr 5. 2019
6.13
May 1. 2019
7.12
17 Trading Days
16.22%
Link
LONG
Sep 3. 2019
5.40
Sep 27. 2019
6.72
18 Trading Days
24.46%
Link
LONG
Dec 9. 2019
4.13
Dec 26. 2019
4.75
12 Trading Days
15.02%
Link
LONG
Apr 7. 2020
7.02
Apr 27. 2020
11.72
13 Trading Days
66.94%
Link
LONG
Nov 24. 2020
5.28
Dec 9. 2020
5.97
10 Trading Days
12.99%
Link
LONG
Jan 11. 2021
5.32
Feb 11. 2021
7.21
22 Trading Days
35.61%
Link
LONG
Jul 21. 2021
5.34
Jul 22. 2021
6.34
1 Trading Days
18.73%
Link
Company Information
Stock Symbol
CEMI
Exchange
NasdaqCM
Company URL
http://www.chembio.com
Company Phone
(631) 924-1135
CEO
John J. Sperzel
Headquarters
New York
Business Address
3661 HORSEBLOCK ROAD, MEDFORD, NY 11763
Sector
Equity
Industry Category
Drugs
Industry Group
Diagnostic Substances
CIK
0001092662
About

Chembio Diagnostics, Inc. develops, manufactures, markets and licenses rapid point-of-care diagnostic tests that detect infectious diseases. It sells its products under its STAT PAK, SURE CHECK, DPP and SampleTainer trademarks. The company was founded on May 5, 2004 and is headquartered in Medford, NY.

Description

Chembio Diagnostics, Inc., together with its subsidiary, Chembio Diagnostic Systems, Inc., develops, manufactures, markets, and licenses rapid point-of-care (POC) diagnostic tests that detect infectious diseases. It offers rapid tests for the detection of HIV and syphilis antibodies. The company's products include lateral flow rapid HIV tests and Dual Path Platform (DPP) HIV 1/2 Assay Test, which detect antibodies to HIV 1 and 2 with visually interpreted results; a DPP HIV-Syphilis multiplex test for the detection of antibodies to HIV and syphilis; and a test for the detection of Hepatitis-C. Chembio Diagnostics, Inc. sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC to develop a POC diagnostic test for traumatic brain injury; and collaboration with an international diagnostics company to develop a POC diagnostic test for a specific type of cancer. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading